These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3467875)

  • 41. Pharmacokinetics of ofloxacin in healthy subjects and patients with impaired renal function.
    Höffler D; Koeppe P
    Drugs; 1987; 34 Suppl 1():51-5. PubMed ID: 3125032
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Pharmacokinetics of ofloxacin in patients with severe renal impairment].
    Bandai H; Tsubakihara Y; Yamato E; Yokoyama K; Okada N; Nakanishi I; Iida N
    Nihon Jinzo Gakkai Shi; 1987 Nov; 29(11):1429-33. PubMed ID: 3482706
    [No Abstract]   [Full Text] [Related]  

  • 43. A preliminary report on the pharmacokinetics of ofloxacin, desmethyl ofloxacin and ofloxacin N-oxide in patients with chronic renal failure.
    White LO; MacGowan AP; Lovering AM; Reeves DS; Mackay IG
    Drugs; 1987; 34 Suppl 1():56-61. PubMed ID: 3481329
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The pharmacokinetics of ofloxacin, desmethyl ofloxacin and ofloxacin N-oxide in haemodialysis patients with end-stage renal failure.
    White LO; MacGowan AP; Mackay IG; Reeves DS
    J Antimicrob Chemother; 1988 Sep; 22 Suppl C():65-72. PubMed ID: 3182464
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Pharmacokinetic study of ofloxacin using saliva concentration in chronic renal failure].
    Tsubakihara Y; Hayashi T; Shoji T; Kitamura E; Okada N; Nakanishi I
    Nihon Jinzo Gakkai Shi; 1994 Mar; 36(3):246-9. PubMed ID: 8196221
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serum and prostatic tissue concentrations of ofloxacin.
    Fujita K; Munakata A
    Clin Ther; 1988; 10 Spec No():32-5. PubMed ID: 3233627
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ofloxacin: serum and skin blister fluid pharmacokinetics in the fasting and non-fasting state.
    Kalager T; Digranes A; Bergan T; Rolstad T
    J Antimicrob Chemother; 1986 Jun; 17(6):795-800. PubMed ID: 3460984
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dose linearity testing of intravenous ofloxacin, a novel gyrase inhibitor.
    Verho M; Korn A; Badian M; Malerczyk V; Waldhäusl W
    Chemotherapy; 1988; 34(3):170-7. PubMed ID: 3166420
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics of ofloxacin after parenteral and oral administration.
    Lode H; Höffken G; Olschewski P; Sievers B; Kirch A; Borner K; Koeppe P
    Antimicrob Agents Chemother; 1987 Sep; 31(9):1338-42. PubMed ID: 3479046
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relative bioavailability of ofloxacin tablets in comparison to oral solution.
    Malerczyk V; Verho M; Korn A; Rangoonwala R
    Curr Med Res Opin; 1987; 10(8):514-20. PubMed ID: 3479296
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Further methodological improvement in antibiotic bone concentration measurements: penetration of ofloxacin into bone and cartilage.
    Wittmann DH; Kotthaus E
    Infection; 1986; 14 Suppl 4():S270-3. PubMed ID: 3469160
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients.
    Kampf D; Borner K; Pustelnik A
    Eur J Clin Pharmacol; 1992; 42(1):95-9. PubMed ID: 1541323
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients.
    Pedersen SS; Jensen T; Hvidberg EF
    J Antimicrob Chemother; 1987 Oct; 20(4):575-83. PubMed ID: 3479419
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ofloxacin pharmacokinetics in chronic renal failure and dialysis.
    Lameire N; Rosenkranz B; Malerczyk V; Lehr KH; Veys N; Ringoir S
    Clin Pharmacokinet; 1991 Nov; 21(5):357-71. PubMed ID: 1773550
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Kinetics of absorption and elimination of ofloxacin in humans after oral and rectal administrations.
    Eboka CJ; Okor RS; Akerele JO; Aigbavboa SO
    J Clin Pharm Ther; 1997 Jun; 22(3):217-20. PubMed ID: 9447477
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics of aztreonam in patients with chronic renal failure.
    Fillastre JP; Leroy A; Baudoin C; Humbert G; Swabb EA; Vertucci C; Godin M
    Clin Pharmacokinet; 1985; 10(1):91-100. PubMed ID: 4038635
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics of ofloxacin and adequacy of maintenance dose for patients on haemodialysis.
    Kampf D; Borner K; Pustelnik A
    J Antimicrob Chemother; 1990 Nov; 26 Suppl D():61-8. PubMed ID: 2286592
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of ofloxacin on the pharmacokinetics of a single intravenous theophylline dose.
    Al-Turk WA; Shaheen OM; Othman S; Khalaf RM; Awidi AS
    Ther Drug Monit; 1988; 10(2):160-3. PubMed ID: 3164150
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics of cefodizime in normal individuals and in patients with renal failure.
    el Guinaidy MA; Nawishy S; Abd el Bary M; Sabbour MS
    Chemotherapy; 1991; 37(2):77-85. PubMed ID: 2032473
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of gender on the pharmacokinetics of ofloxacin.
    Sowinski KM; Abel SR; Clark WR; Mueller BA
    Pharmacotherapy; 1999 Apr; 19(4):442-6. PubMed ID: 10212016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.